Pharmaceutical Supplier Qualification: Why Approval Is Only the Beginning

Pharmaceutical organisations are increasingly dependent on third parties. 

Manufacturers, testing laboratories, logistics providers, packaging suppliers, contract development organisations, software vendors and specialist service providers can all form part of the chain responsible for getting a medicinal product to a patient. 

That model gives organisations access to specialist capability, additional capacity and global reach. It also creates risk. 

One of the most persistent mistakes in supplier management is treating qualification as a hurdle to clear before a vendor is added to an approved supplier list. A questionnaire is completed, an audit is performed, actions are closed and the supplier receives an approved status. Once that happens, attention moves to the next supplier. In a regulated pharmaceutical environment, approval is not the end of supplier qualification. It is the beginning of ongoing assurance. The real question is not whether a supplier was suitable on the day it was approved. It is whether the organisation can continue to demonstrate that the supplier remains capable, compliant and appropriate for the activities entrusted to it. When supplier oversight becomes a documentation exercise rather than an operational one, changes in risk can remain invisible until an inspection, deviation, batch failure or supply interruption exposes them. 

Supplier qualification is not procurement due diligence 

Commercial supplier selection and GxP supplier qualification serve different purposes. 

A procurement exercise might reasonably assess price, capacity, lead time, contractual terms, financial stability and service levels. Those factors matter. But a pharmaceutical quality function has another question to answer: Can this organisation reliably perform the activity we are entrusting to it without creating an unacceptable risk to product quality, patient safety, data integrity or regulatory compliance? That distinction matters because the cheapest provider may not be the lowest-risk provider. A supplier with a strong commercial reputation may not have the right controls for the specific GxP activity being outsourced. An organisation with recognised certifications may still have weaknesses in the processes that matter most to your product. Qualification therefore has to be specific to the activity, product and regulatory exposure involved. 

Why the supplier questionnaire is not enough 

Supplier questionnaires are useful. They can provide initial information about licences, certifications, inspection history, organisational structure, quality systems and technical capability. But they are only one source of evidence. A completed questionnaire tells you what the supplier says its system does. It does not necessarily tell you what happens when production is under pressure, when a deviation crosses departmental boundaries, when data do not support the expected conclusion, when an experienced employee leaves or when a subcontractor changes. That gap between documented process and operational reality is exactly why risk-based auditing matters. A quality system can look excellent on paper and operate very differently in practice. Effective supplier qualification has to go beyond document existence and test whether controls actually work. 

Qualification should be risk-based 

Not every supplier requires the same level of scrutiny. 

A company providing office stationery does not create the same GxP exposure as a contract manufacturer producing commercial batches. A laboratory generating release data does not carry the same risk as a general professional-services provider. A mature supplier-qualification programme therefore applies proportionality. Key considerations include product impact. Could the supplier's activities directly affect the identity, strength, quality, purity or safety of the product? Regulatory impact also matters. Is the supplier performing an activity required under a licence, marketing authorisation or regulated quality system? Then there is data impact. Does the supplier generate, process, review or store data used to support batch disposition, regulatory submissions or other critical decisions? Supply-chain dependency should be considered too. Would failure of the supplier interrupt product supply or prevent patients receiving treatment? Subcontracting can introduce another layer of exposure. Does the organisation perform the activity itself, or are important elements passed further down the supply chain? Finally, existing compliance information should influence the approach. Previous inspections, audit findings, recurring deviations, complaints and performance trends can all change the level of assurance required. Taken together, these factors should determine the qualification route. That might range from a desktop review to a remote assessment, an onsite audit or an enhanced oversight programme. 

An audit should answer a risk question 

One of the most common weaknesses in supplier auditing is starting with a checklist rather than a question. 

A checklist can demonstrate that an audit took place. It does not necessarily demonstrate that the right things were examined. Before fieldwork begins, the organisation should understand what it is trying to establish. For a contract laboratory, the key question might be whether the site can generate reliable, traceable and scientifically defensible data capable of supporting release decisions. For a contract manufacturer, the focus might be whether the site's systems can consistently control the process, investigate deviations properly and maintain the validated state. For a logistics provider, temperature control, excursion management, chain of custody, security and escalation may be central. Those questions drive a more meaningful audit than simply asking whether the supplier has SOPs. Effective GxP auditing follows processes through. A deviation can be traced from identification through investigation, root cause, CAPA and effectiveness verification. Analytical data can be followed from generation through review and approval. Training records can be tested against genuine competency. Change controls can be examined to understand whether risks are assessed before implementation. This is where gaps between written systems and operational reality become visible. 

Look at interfaces, not just departments 

Many supplier failures do not occur because one individual process is absent. They occur at the interfaces between processes and teams. 

A change initiated by manufacturing may have consequences for validation, regulatory commitments, analytical methods, stability, supply planning and quality oversight. If those functions do not communicate effectively, the technical change may be managed correctly within one department while creating risk elsewhere. The same applies to deviations. A manufacturing event may be investigated locally, but the wider impact on released batches, other products, other sites or regulatory filings may not be properly assessed. Auditors should therefore pay attention to handoffs, escalation routes and decision-making. Who owns the issue? Who is consulted? How is impact assessed? How are disagreements resolved? How is evidence recorded? Those questions often reveal more than a perfectly formatted SOP. 

Supplier qualification does not end when the audit closes 

One of the most dangerous points in the supplier lifecycle is immediately after approval. 

The audit is complete. Actions are closed. The quality agreement has been signed. The vendor becomes approved. Then attention moves elsewhere. But supplier risk changes. Personnel change. Sites change. Equipment changes. Regulations evolve. Ownership changes. Subcontractors change. Volumes increase. Financial pressure appears. New products are introduced. A supplier judged suitable three years ago is not automatically suitable today. Ongoing qualification therefore requires indicators capable of showing when the risk profile has changed. Useful signals can include deviation trends, complaints, rejected or failed batches, delivery performance, change notifications, regulatory inspection outcomes, recurring CAPAs, data-integrity concerns, quality agreement breaches and significant organisational changes. The objective is not to collect every available metric. It is to identify the signals that matter and make sure they trigger action. 

Audit frequency should follow evidence 

Audit frequency should also follow evidence. A stable, lower-risk supplier should not automatically require the same oversight as a critical partner experiencing recurring deviations, inspection findings or organisational change. Risk should be able to move the audit programme in either direction. Increased risk may justify earlier or deeper audit activity; strong performance may support a lighter model. The goal is not the maximum number of audits. It is enough oversight to make informed, defensible decisions and focus specialist resource where failure would matter most. 

What happens when you cannot audit everyone? 

This is a common challenge for growing pharmaceutical and biotech companies. 

The supplier network expands faster than internal quality headcount. Audit schedules grow. Suppliers sit across multiple countries and time zones. Specialist expertise is needed for particular technologies or regulatory regimes. The answer should not be to reduce assurance to a paperwork exercise. External audit capability can be used to extend internal capacity while preserving the organisation's governance and accountability. This can include individual supplier audits, international audit programmes, backlog recovery, specialist technical audits or an outsourced risk-based audit function. TDP's Global GxP Auditing service is designed around that principle: providing experienced audit capability across global supply chains while aligning the scope, risk approach and deliverables to the client's own quality system. Outsourcing the audit does not mean outsourcing responsibility. The pharmaceutical organisation still needs to understand why the supplier is being audited, what risks matter, how findings will be assessed and what happens after the report is issued. 

Findings need context, not just classification 

An audit report should help the organisation make decisions. 

A list of observations classified as critical, major or minor is useful, but it is not enough on its own. The business needs to understand what the findings mean. Could they affect product already supplied? Do they undermine confidence in data? Is there a systemic issue or an isolated failure? Does the finding create a regulatory commitment? Is immediate containment required? Are other suppliers or products exposed to the same risk? Good audit reporting connects the observation to its potential consequence and provides enough evidence for the client to determine the appropriate response. That is especially important when senior leaders who were not present at the audit need to make rapid decisions. 

Quality agreements must reflect reality 

Supplier qualification and quality agreements are often treated as separate activities. In practice, they should reinforce one another. A quality agreement should reflect the real operating model. Who notifies whom of a significant deviation? How quickly? Which changes require prior approval? Who owns investigation activities? Who is responsible for regulatory communication? What records must be available for review? How are complaints, recalls and inspections handled? If the agreement describes a theoretical governance model that does not match day-to-day operations, it offers limited protection. Audit findings and operational experience should therefore feed back into quality agreements and supplier-management processes. The aim is a living oversight system, not a static contract. 

From approved supplier to assured supply chain 

The most effective supplier qualification programmes share a common characteristic: they are designed around risk rather than administration. They use appropriate initial qualification, meaningful audits, clear quality agreements and ongoing performance data as parts of the same system. They recognise that supplier risk changes over time. And they create a mechanism for acting when those changes occur. For pharmaceutical organisations, that matters because the supplier may perform the activity, but the consequences of failure do not remain neatly with the supplier. They come back to the licence holder, sponsor, manufacturer, MAH or organisation placing the product on the market. 

The strongest question is therefore not, "Is this supplier approved?" It is, "What evidence do we have that this supplier remains under control?" 

How TDP can help 

If you need practical support strengthening your pharmaceutical quality, regulatory or operational model, TDP can provide the right expertise at the right time. Request a call back to discuss where support would create the most value.